Vanda Pharmaceuticals reports positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder

30 September 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) on Tuesday reported positive topline results from its pivotal Phase III study of HETLIOZ (tasimelteon) 20mg in adu...